This study shows the therapeutic value of the combination of a DNA ligase IV inhibitor and DNA-damaging agents (doxorubicin and/or γ-radiation) for the treatment of anaplastic thyroid cancer. Here, LIG4 is linked to thyroid gland undifferentiated (anaplastic) carcinoma.